We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Medical technology company Conmed said its board authorized the repurchase of
up to $50 million of the company's common shares from time to time in the open
market or in private transactions.
Calypte Biomedical said that it has started trials of its Aware rapid HIV-1/2
test in Africa. The trials will evaluate the test using blood, saliva and urine
as specimens.
NIR Diagnostics, a developer of near-infrared handheld reagentless medical instruments,
announced that, further to the tax assisted financing announced on Dec. 31,
2004, the company has exercised its rights to reacquire 100 percent interest
in the GlucoNIR business.
Biopotential Capital, a capital pool company listed on the TSX Venture Exchange,
announced that it has signed the share exchange agreement with Osta Biopharma,
a Montreal-based private company specializing in developing novel diagnostics
and therapeutics for osteoporosis and osteoarthritis.
Regeneration Technologies (RTI), the Florida-based
processor of orthopedic, cardiovascular and other allograft implants, announced
that the company's bone paste product has received 510(k) clearance from the
FDA.
Diagnostics manufacturer Inverness Medical Innovations has signed a deal to
purchase devicemaker Ischemia Technologies for approximately $22.4 million in
stock.
Baxter Healthcare has received 510(k) clearance from the FDA to market a wireless
pump connectivity interface that enables hospitals to connect Baxter's Colleague
CX infusion pump to its Patient Care System.
Alimera Sciences, an ophthalmic pharmaceutical company, and Control Delivery
Systems (CDS), a maker of innovative drug delivery systems for the eye, announced
a worldwide agreement to co-develop and market a new pharmacologic treatment
indicated for diabetic macular edema (DME), a major cause of vision loss in
people suffering from diabetic retinopathy.
ChromaVision Medical Systems, a technology and services resource for pathologists,
oncologists and the pharmaceutical industry, announced that it is changing the
name of the corporation to Clarient in order to better reflect a new strategy,
direction and business plan that have been expanded to serve three distinct
markets.